Beilu Pharmaceutical

Add links
Source: Wikipedia, the free encyclopedia.
Beijing Beilu Pharmaceutical Co., Ltd.
Beilu Pharma
Company typePublic
SZSE: 300016
IndustryPharmaceutical
Founded1992
HeadquartersBeijing
Area served
China, Pakistan,[1] Peru,[2] etc.
ProductsJiuwei Zhenxin Granules
Websitewww.beilupharma.com

Beilu Pharmaceutical (alternatively as Beilu Pharmaceuticals;

gadopentetate dimeglumine injections,[11] and Iohexol injections.[12]

Beilu Pharma is headquartered in Beijing,[13] and was financed by Infotech in 2008.[14] It had reached required standards to float shares on the Shenzhen second board market in May 2009.[15] In October, Beilu officially landed on the ChiNext[16][17] under the ticker symbol "SHE: 300016".[18]

In 2014, Beilu Pharma invested 30 million yuan in Geneseeq Technology.

net profit surpassed 118 million yuan in 2017.[22] In 2020, Beilu raised $70.42 million.[23]

References

  1. ^ Ramay, Ali (August 12, 2023). "Exploring the path of healthcare collaboration: Beijing Beilu Pharmaceutical Company". 24 Digital.
  2. ^ "DIGEMID Strengthens Regulations on Imported Pharmaceutical Products". Andina. September 30, 2013. Archived from the original on December 13, 2023.
  3. ^ Jordi Rimola; Zhirong Zeng (December 13, 2018). "Intra-Cavitary Contrast-Enhanced Ultrasound: A Novel Radiation-Free Method for Detecting Abscess-Associated Penetrating Disease in Crohn's Disease". Oxford University Press.
  4. ^ "Beilu Pharmaceutical receives GMP certificate". Reuters. December 29, 2016.
  5. ^ Wang Weidong; Jean Zhang (August 6, 2013). "An Analysis on the Concept of State-Owned Shares in Listed Companies and Their Obligation to Transfer". Lexology.com.
  6. ^ Portia Liang (June 12, 2022). "Impact of COVID-19 Pandemic on Pharmaceutical Manufacturing in China" (PDF). Center for Global Development. Archived (PDF) from the original on December 11, 2023.
  7. ISSN 1038-8761
    .
  8. ^ "Beilu Pharmaceutical Approved to List on the Shenzhen Stock Exchange". Interfax. August 6, 2009. Archived from the original on December 13, 2023.
  9. ^ Chao Deng (September 12, 2012). "UBS China Looks to Smaller Firms for Growth". The Wall Street Journal.
  10. ISBN 978-981-10-0901-3
    .
  11. ^ Jun Ma; Tao Jiang (September 25, 2015). "Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients". Oxford University Press.
  12. ^ Yuanwei Liu; Ying Ming (July 10, 2023). "Radiomics and Ki-67 index predict survival in clear cell renal cell carcinoma". Oxford University Press.
  13. ^ Shomron Ben-Horin; Jian Zhang (January 11, 2017). "Diffusion-weighted MRI Enables to Accurately Grade Inflammatory Activity in Patients of Ileocolonic Crohn's Disease: Results from an Observational Study". Oxford University Press. Archived from the original on December 13, 2023.
  14. ^ "Beilu Pharma Raises 67 Million RMB". BioSpace. August 26, 2008.
  15. ^ Vivian Wai-yin Kwok (Forbes Staff) (May 6, 2009). "The Nasdaq of China is Coming". Forbes. Archived from the original on May 9, 2009.
  16. ISSN 1087-0156
    .
  17. ^ "Beyond Borders: Global Biotechnology Report 2010" (PDF). Ernst & Young. April 28, 2010. Archived (PDF) from the original on December 13, 2023.
  18. ^ "Beilu Pharmaceutical Decides to End Its Agomelatine Development Project". BioSpace. July 19, 2011. Archived from the original on December 11, 2023.
  19. ^ "Geneseeq Technology Signs Investment Agreement with Beilu Pharmaceutical". MarketScreener. August 26, 2014. Archived from the original on December 11, 2023.
  20. ^ "Beilu Pharmaceutical to establish industry buyout fund worth 610 mln yuan". Reuters. April 28, 2016.
  21. ISSN 0143-7690
    .
  22. ISBN 978-981-15-1648-1
    .
  23. ^ "China Diagnostic Imaging Market Outlook to 2025". GlobalData. June 30, 2020.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Beilu_Pharmaceutical&oldid=1211537006"